Abbisko Cayman Limited ( (HK:2256) ) has provided an announcement.
Abbisko Cayman Limited announced its annual results for 2024, highlighted by significant progress in its clinical programs. The company reported positive results from its global phase III study of pimicotinib in treating tenosynovial giant cell tumor, showcasing a high objective response rate and favorable safety profile. Additionally, Abbisko received approval from China’s Center for Drug Evaluation to initiate a registrational study for irpagratinib in hepatocellular carcinoma, marking a key advancement in its oncology pipeline. These developments are expected to strengthen Abbisko’s position in the biopharmaceutical industry and potentially offer new treatment options for patients.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a biopharmaceutical company focused on the development of innovative medicines, particularly in oncology. The company is engaged in research and development of targeted therapies, with a market focus on addressing unmet medical needs in cancer treatment.
YTD Price Performance: 31.09%
Average Trading Volume: 2,827,122
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$4.1B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.